Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Cash & Equivalents for 5 consecutive years, with $496.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 43.91% to $496.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $496.3 million through Dec 2025, up 43.91% year-over-year, with the annual reading at $496.3 million for FY2025, 43.91% up from the prior year.
  • Cash & Equivalents hit $496.3 million in Q4 2025 for Krystal Biotech, up from $392.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $496.3 million in Q4 2025 to a low of $140.7 million in Q1 2023.
  • Historically, Cash & Equivalents has averaged $316.0 million across 5 years, with a median of $343.1 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: plummeted 52.56% in 2022 and later skyrocketed 155.08% in 2024.
  • Year by year, Cash & Equivalents stood at $341.2 million in 2021, then tumbled by 52.56% to $161.9 million in 2022, then surged by 121.33% to $358.3 million in 2023, then dropped by 3.76% to $344.9 million in 2024, then soared by 43.91% to $496.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for KRYS at $496.3 million in Q4 2025, $392.6 million in Q3 2025, and $353.8 million in Q2 2025.